A Volumetric-Imaging Software Platform for Enabling Optimized Workflow of Multidisciplinary Lumpectomy Assessment
用于优化多学科肿瘤切除评估工作流程的体积成像软件平台
基本信息
- 批准号:10011691
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAddressAdoptedAgreementBreastChicagoClientClinicalCollaborationsColorCommunicationComputer softwareDataDevicesEnvironmentFoundationsGoalsHistologyHospitalsImageImaging DeviceInkLaboratoriesLeftLegal patentLocationMalignant NeoplasmsMarket ResearchMedical DeviceOperating RoomsOperative Surgical ProceduresOutpatientsPathologistPathologyPatientsPerformancePhasePositioning AttributePostoperative PeriodRepeat SurgeryReportingResearchResidual TumorsRiskRoentgen RaysServicesSlideSmall Business Innovation Research GrantSoftware ValidationSpecialistSpecimenSurgeonSurgical suturesTechniquesTechnologyTelephoneThinnessThree-Dimensional ImageThree-Dimensional ImagingTimeTissuesUniversitiesValidationVisualizationWomanWorkbasebreast lumpectomycatalystclinical applicationcommercial applicationcostcyber securitydesignimagerimaging softwareimprovedinnovationmalignant breast neoplasmmultidisciplinaryoperationovertreatmentradiologistsharing platformthree-dimensional visualizationtooltumorunnecessary treatmentuser-friendlyvirtual
项目摘要
Project Summary
Clarix Imaging (CI) is a startup medical device company spun out of The University of Chicago (UC) to develop
a real-time X-ray volumetric specimen imager (VSI) device and software solution for enabling accurate and
rapid 3D margin assessment (MA) in the operating room (OR) and pathology laboratory. We propose this SBIR
Phase I research to establish the feasibility of a VSI-based software platform for enabling multidisciplinary
workflows for lumpectomy assessment, which lays the foundation for optimizing an innovative, user-friendly
workflow with optimized MA accuracy and efficiency for routine clinical application. The annual performance of
>200,000 outpatient breast lumpectomies in the US has a high reoperation rate (25%). Meanwhile, no tumor is
found in up to 63% of these reoperations, resulting in simultaneous over-treatment of unnecessary healthy
tissues and under-treatment as tumor may remain in the patient’s breast. A leading cause of this problem is the
high discordance among surgeons, radiologists, and pathologists on specimen orientation due to the lack of
adequate tools facilitating their collaboration in the existing MA workflow. The current practice relies on
surgeon’s sutures, specimen radiographs, and pathologist’s inking to localize positive margin (PM). Studies
showed that the discordance rate on PM location among surgeons, radiologists, and pathologists range from
31% to 52%. There is an unmet need for an improved workflow yielding better agreement among the
multidisciplinary team. Recently, CI developed the VSI device for real-time full 3D lumpectomy specimen
imaging in the OR. The availability of VSI provides the foundation for innovative software platform and
applications that can enable better multidisciplinary workflows for lumpectomy assessment. The product of this
SBIR will be a software platform that allows real-time, remote shared visualization and annotation of full 3D VSI
images by multiple users. The software will also enable virtual inking by the surgeon to communicate a precise
specimen orientation across the entire multidisciplinary team. We envision in the next 3-4 years to introduce
the proposed software platform as the standard clinical workflow, and together with the VSI device, they
complete the CI solution for lumpectomy MA. The Specific Aims of the Phase I project are (1) to create and
validate the software platform for shared multi-user visualization of VSI data, and (2) to create and verify the
virtual inking application for enabling optimized MA workflow. Reaching these Aims will firmly establish the
feasibility of using the proposed VSI-based software platform to enable optimized multidisciplinary MA
workflow, and reduce the technical risk of Phase II work, which includes (1) optimizing the software platform
cybersecurity and robustness within a hospital network environment, (2) fully developing the virtual inking
technique optimally integrated in the clinical workflow integration, and (3) conducting clinical workflow
validation with patient specimens and prepare for FDA submission. The 6,000 ORs performing lumpectomies
and 9,000 pathology labs in the US are all using dated suture-based workflows and are ready to adopt our
software, representing ~150M annual addressable market opportunity. We plan to introduce the VSI device to
customers first. It will serve as a catalyst for the software product, which will be offered either bundled with VSI
or as a separate, value-added service.
项目摘要
Clarix Imaging(CI)是一家从芝加哥大学(UC)分拆出来的初创医疗设备公司,
实时X射线体积样本成像仪(VSI)设备和软件解决方案,
在手术室(OR)和病理实验室进行快速3D边缘评估(MA)。我们提出这个SBIR
第一阶段研究,以确定基于VSI的软件平台的可行性,
乳房肿瘤切除术评估的工作流程,为优化创新的、用户友好的
优化MA准确性和效率的工作流程,适用于常规临床应用。全年业绩
在美国,超过200,000例门诊乳房肿块切除术的再手术率很高(25%)。与此同时,
在高达63%的再次手术中发现,导致同时过度治疗不必要的健康
组织和治疗不足,因为肿瘤可能留在患者的乳房中。这个问题的主要原因是
外科医生、放射科医生和病理科医生之间关于标本方向的高度不一致,
适当的工具,促进他们在现有的MA工作流程中的合作。目前的做法依赖于
外科医生的缝合线、标本X光片和病理学家的墨迹以定位阳性边缘(PM)。研究
结果显示,外科医生、放射科医生和病理科医生之间PM位置的不一致率从
31%到52%。有一个未得到满足的需要,即需要改进工作流程,以便在工作人员之间达成更好的协议。
多学科团队。最近,CI开发了用于实时全3D乳房肿瘤切除术标本的VSI设备
手术室里的影像VSI的可用性为创新的软件平台和
这些应用程序可以为乳房肿瘤切除术评估提供更好的多学科工作流程。这个产品
SBIR将是一个软件平台,允许实时、远程共享可视化和完整3D VSI注释
多个用户的图片。该软件还将使外科医生能够虚拟着墨,以传达精确的信息。
在整个多学科团队中进行标本定向。我们设想在未来3-4年内,
建议的软件平台作为标准临床工作流程,与VSI器械一起,
完成乳房肿瘤切除术MA的CI溶液。第一阶段项目的具体目标是(1)创建和
验证VSI数据共享多用户可视化的软件平台,以及(2)创建和验证
虚拟墨水应用程序,用于实现优化的MA工作流程。实现这些目标将坚定地建立
使用拟议的基于VSI的软件平台实现优化的多学科MA的可行性
工作流程,降低二期工作的技术风险,其中包括(1)优化软件平台
医院网络环境中的网络安全性和鲁棒性,(2)充分开发虚拟墨水
技术最佳地集成在临床工作流程集成中,以及(3)进行临床工作流程
使用患者样本进行验证,并准备向FDA提交。6,000个手术室在做乳房肿瘤切除术
在美国,9,000个病理学实验室都在使用过时的基于缝合的工作流程,并准备采用我们的
软件,代表每年约1.5亿的潜在市场机会。我们计划将VSI设备引入
顾客至上。它将作为软件产品的催化剂,该软件产品将与VSI捆绑提供
或者作为单独的增值服务。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christian Wietholt其他文献
Christian Wietholt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant